8. Immunomodulators and antineoplastics

8.2. Antineoplastics and supportive medicines

8.2.1. Cytotoxic medicines

Docetaxel

### Summary of evidence and Expert Committee recommendations

In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for docetaxel on the complementary list of the EML for use in treatment protocols for metastatic breast cancer was specifically endorsed. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for metastatic breast cancer is attached.